Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blincyto in Children with ALL and MRD-Positivity Pre/Post HSCT
NCT04785547Phase 2Terminated
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL). Started Dec 2020; status: terminated.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04785547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785547.